Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP31969 vs Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949Phase 2Recruiting
- Sponsor
- Acesion Pharma
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised trial of AP31969 in Atrial fibrillation (AFib) (5 arms), sponsored by Acesion Pharma. Primary endpoint: Atrial fibrillation burden. Started Oct 2025; status: recruiting.
02
Drugs
AP31969
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07267949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267949.